检索结果-南通市图书馆

在线全文

学校读者我要写书评

暂无评论

软黏土基坑开挖诱发坑外地表沉降的时效解

岩土工程学报 2024年第10期46卷 2041-2050页

作者：应宏伟熊一帆李冰河吕唯程康张金红河海大学岩土力学与堤坝工程教育部重点实验室江苏南京210024 浙江大学滨海和城市岩土工程研究中心浙江杭州310058 浙江省建筑设计研究院浙江杭州310006 中铁十一局集团有限公司湖北武汉430061

对比理论和实测研究成果,发现既有坑外地表沉降计算方法不适用于蠕变效应显著的软土基坑。借助Lame方程和三参量黏弹性地基模型,推导得到柔性挡墙任意变位诱发坑外地表沉降的时效半解析解;将理论计算方法应用于杭州软土地区的两个深基... 详细信息

对比理论和实测研究成果,发现既有坑外地表沉降计算方法不适用于蠕变效应显著的软土基坑。借助Lame方程和三参量黏弹性地基模型,推导得到柔性挡墙任意变位诱发坑外地表沉降的时效半解析解;将理论计算方法应用于杭州软土地区的两个深基坑工程实例,分析了从基坑开挖到地下室回筑的施工全过程中坑外地表沉降的发展规律。结果表明:(1)软土蠕变诱发不依赖于挡墙附加侧移的地表沉降,不仅导致软土基坑开挖期间的地表最大沉降与挡墙最大侧移之比远大于非软土基坑,而且引起坑外土体在地下室回筑期的持续沉降;(2)软土蠕变诱发的地表沉降随挡墙侧移的增大而增大,表现为凹槽沉降模式;(3)深厚软土深基坑的地表最大沉降与挡墙最大侧移之比主要受软土蠕变性和施工时间等因素的影响,与挡墙侧移量的关系不明显。

关键词：基坑开挖地表沉降软黏土蠕变时效解

ECOLOGICAL EFFECTS OF NITROGEN DEPOSITION ON URBAN FORESTS: AN OVERVIEW

在线全文

学校读者我要写书评

暂无评论

Frontiers of Agricultural Science and Engineering 2022年第3期9卷 445-456页

作者： Enzai DU Nan XIA Yuying GUO Yuehan TIAN binghe li Xuejun liU Wim DE VRIES State Key Laboratory of Earth Surface Processes and Resource Ecology Faculty of Geographical ScienceBeijing Normal UniversityBeijing 100875China School of Natural Resources Faculty of Geographical ScienceBeijing Normal UniversityBeijing 100875China National Academy of Agriculture Green Development Key Laboratory of Plant-Soil Interactions of Ministry of EducationCollege of Resources and Environmental SciencesChina Agricultural UniversityBeijing 100193China Wageningen University and Research Environmental ResearchPO Box 47NL-6700 AA Wageningenthe Netherlands Wageningen University and Research Environmental Systems Analysis GroupPO Box 47NL-6700 AA Wageningenthe Netherlands

The global urban area is expanding continuously,resulting in unprecedented emissions and deposition of reactive nitrogen(N)in urban ***,large knowledge gaps remain in the ecological effects of N deposition on urban forests that provide key ecosystem services for an increasing majority of city *** current understanding of the spatial patterns and ecological effects of N deposition in urban forests was synthesized based on a literature review of observational and experimental *** deposition generally increases closer to cities,resulting in an urban hotspot *** components of N deposition also shift across urban-suburban-rural gradients,showing higher ratios of ammonium to nitrate in and around urban *** ecological effects of N deposition on urban forest ecosystems are overviewed with a special focus on ecosystem N cycling,soil acidification,nutrient imbalances,soil greenhouse gas emissions,tree growth and forest productivity,and plant and soil microbial *** distinct effects of unprecedented N deposition on urban forests are discussed in comparison with the common effects in natural *** the existing research efforts,several key research needs are highlighted to fill the knowledge gaps in the ecological effects of N deposition on urban forests.

关键词： biodiversity carbon sequestration nitrogen deposition nutrient imbalance soil acidification urban forest

Strain-promoted S-arylation and alkenylation of sulfinamides using arynes and cyclic alkynes

在线全文

学校读者我要写书评

暂无评论

Science China Chemistry 2024年第3期67卷 928-935页

作者： Xi Zou Boming Shen Gao-lin li Qian liang Yanhua Ouyang binghe Yang Peiyuan Yu Bing Gao State Key Laboratory of Chemo/Bio-Sensing and Chemometrics College of Chemistry and Chemical EngineeringInstitute of Chemical Biology and NanomedicineHunan UniversityChangsha 410082China Department of Chemistry and Shenzhen Grubbs Institute Guangdong Provincial Key Laboratory of CatalysisSouthern University of Science and TechnologyShenzhen 518055China

The conversion of commercially available chiral sulfinamides into pharmaceutically useful chiral sulfoximines via direct SIVfunctionalization is synthetically attractive but challenging due to the competitive reaction of N-functionalization. Herein, we disclose a novel strain-release strategy to access stereospecific and chemoselective SIV-arylation and alkenylation of sulfinamides using arynes and strained cyclic alkynes. This method tolerates an unprecedented chemical diversity of functional groups attached to the nitrogen center(N-R). The origin of the high SIV-selectivity is elucidated by density functional theory calculations, suggesting a stepwise mechanism for the aryne substrates and a concerted mechanism for the cyclic alkynes.

关键词： arylation alkenylation sulfoximines sulfinamides arynes

Disitamab vedotin,a HER2-directed antibody-drug conjugate,in patients with HER2-overexpression and HER2-low advanced breast cancer:a phase I/Ib study

在线全文

学校读者我要写书评

暂无评论

Cancer Communications 2024年第7期44卷 833-851页

作者： Jiayu Wang Yunjiang liu Qingyuan Zhang Wei li Jifeng Feng XiaojiaWang Jianmin Fang Yiqun Han binghe Xu Department of Medical Oncology Cancer HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijingP.R.China Breast Center The Fourth Hospital of Hebei Medical UniversityShijiazhuangHebeiP.R.China Department of Breast Medicine Harbin Medical University Cancer HospitalHarbinHeilongjiangP.R.China Department of Medical Oncology The First Hospital of Jilin UniversityChangchunJilinP.R.China Department of Medical Oncology Jiangsu Cancer HospitalNanjingJiangsuP.R.China Department of Breast Medicine Zhejiang Cancer HospitalHangzhouZhejiangP.R.China School of life Science and Technology Tongji UniversityShanghaiP.R.China

Background:Disitamab vedotin(DV;RC48-ADC)is an antibody-drug conjugate comprising a human epidermal growth factor receptor 2(HER2)-directed antibody,linker and monomethyl auristatin *** studies have shown that DV demonstrated potent antitumor activity in preclinical models of breast,gastric,and ovarian cancers with different levels of HER2 *** this pooled analysis,we report the safety and efficacy of DV in patients with HER2-overexpression and HER2-low advanced breast cancer(ABC).Methods:In the phase I dose-escalation study(C001 CANCER),HER2-overexpression ABC patients received DV at doses of 0.5-2.5 mg/kg once every two weeks(Q2W)until unacceptable toxicity or progressive *** dose range,safety,and pharmacokinetics(PK)were *** phase Ib dose-range and expansion study(C003 CANCER)enrolled two cohorts:HER2-overexpression ABC patients receiving DV at doses of 1.5-2.5 mg/kg Q2W,with the recommended phase 2 dose(RP2D)determined,andHER2-lowABC patients receiving DV at doses of 2.0 mg/kg Q2W to explore the efficacy and safety of DV in HER2-low ***:Twenty-four patients with HER2-overexpression ABC in C001 CANCER,46 patients with HER2-overexpressionABCand 66 patients with HER2-low ABC in C003 CANCER were *** 2.0 mg/kg RP2D Q2W,the confirmed objective response rates were 42.9%(9/21;95%confidence interval[CI]:21.8%-66.0%)and 33.3%(22/66;95%CI:22.2%-46.0%),with median progression-free survival(PFS)of 5.7 months(95%CI:5.3-8.4 months)and 5.1 months(95%CI:4.1-6.6 months)for HER2-overexpression and HER2-low ABC,***(≥5%)grade 3 or higher treatment-emergent adverse events included neutrophil count decreased(17.6%),gamma-glutamyl transferase increased(13.2%),asthenia(11.0%),white blood cell count decreased(9.6%),peripheral neuropathy such as hypoesthesia(5.9%)and neurotoxicity(0.7%),and pain(5.9%).Conclusion:DV demonstrated promising efficacy in HER2-overexpression and HER2-low ABC,with a favorable safety profile at

关键词： antibody-drug conjugate breast cancer clinical trials disitamab vedotin HER2-low HER2-overexpression

An immunogenic cell death-related signature for prediction of prognosis and response to immunotherapy in breast cancer

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Chinese Medical Journal 2024年第4期137卷 487-489页

作者： Cong li Fengzhu Guo Jingtong Zhai Xiaohan liu Zhijun li binghe Xu Department of Medical Oncology National Cancer CenterNational Clinical Research Center for CancerCancer HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing 100021China Department of Medical Oncology Sun Yat-sen University Cancer CenterGuangzhouGuangdong 510060China Department of Medical Oncology Beijing HospitalNational Center of GerontologyInstitute of Geriatric MedicineChinese Academy of Medical SciencesBeijing 100730China Department of Histology and Embryology Basic Medical CollegeChina Medical UniversityShenyangLiaoning 110122China

To the Editor:Tumor immune microenvironment plays a key role in breast cancer development and progression,which determines the long-term survival of breast cancer *** data have revealed that the application of cancer immunotherapy has some limitations,including generating weak immune responses due to inadequate delivery of immunostimulants to the immune cells.^([1])Thus,current clinical efforts are primarily focused on developing immune-based chemotherapy that can convert non-responders to responders.^([2])Immunogenic cell death(ICD)is a form of regulated cell death that is sufficient to activate an adaptive immune response.

关键词： breast immunotherapy chemotherapy

在线全文

学校读者我要写书评

暂无评论

工程签证存在的问题、原因及应对措施

城镇供水 2007年第1期 58-59页

作者：李炳和山东省莱西市自来水公司

工程签证是工程建设管理的一项重要内容，它是保证被签证项目工程质量的重要组成部分，影响着工程造价的正确性和合理性。建设项目的工程签证，主要有隐蔽工程签证、工程变更签证、定额缺项项目工程量的签证、费用项目的签证、施工期间... 详细信息

工程签证是工程建设管理的一项重要内容，它是保证被签证项目工程质量的重要组成部分，影响着工程造价的正确性和合理性。建设项目的工程签证，主要有隐蔽工程签证、工程变更签证、定额缺项项目工程量的签证、费用项目的签证、施工期间出现的不可抗力及对此进行处理的签证等。从工程竣工结算审计过程中反映的情况看，当前工程签证中出现的问题主要集中体现在以下十个方面：

关键词：工程签证建设项目原因工程建设管理组成部分工程质量工程造价工程变更

在线全文

学校读者我要写书评

暂无评论

软黏土超深基坑的时变性状分析及简化算法

地下空间与工程学报 2023年第S2期19卷 758-766页

作者：李冰河应宏伟程康浙江省建筑设计研究院杭州310006 河海大学岩土力学与堤坝工程教育部重点实验室南京210198 浙江大学滨海和城市岩土工程研究中心杭州310058 中铁十一局集团有限公司武汉430061

针对杭州某复杂环境下深厚软黏土超深基坑工程,通过探讨一期基坑实测结果与现行行业规程推荐方法计算结果差距较大的原因,研究了土体蠕变、混凝土支撑收缩徐变等因素对围护结构变形的影响,基于规程的弹性抗力法,引入考虑土体蠕变的水平... 详细信息

针对杭州某复杂环境下深厚软黏土超深基坑工程,通过探讨一期基坑实测结果与现行行业规程推荐方法计算结果差距较大的原因,研究了土体蠕变、混凝土支撑收缩徐变等因素对围护结构变形的影响,基于规程的弹性抗力法,引入考虑土体蠕变的水平地基反力系数的比例系数m的实用简化公式和混凝土支撑徐变影响的弹性模量公式,提出了软土超深基坑考虑时变效应的支护结构简化改进计算方法。分析表明,杭州深厚软黏土基坑的时变效应明显,当基坑施工周期较长时,土体流变和支撑徐变引起的位移可达墙体总位移的40%,现行规程推荐的围护体变形计算结果明显偏小,而提出的改进简化计算方法可以较好地模拟基坑施工历时对变形的影响。

关键词：软黏土土体蠕变混凝土徐变时变效应超深基坑

考虑开挖全过程的基坑坑外任意地表沉降实用计算方法

在线全文

学校读者我要写书评

暂无评论

中南大学学报（自然科学版） 2023年第5期54卷 1851-1862页

作者：程康徐日庆应宏伟李冰河张金红中铁十一局集团有限公司湖北武汉430061 浙江大学滨海和城市岩土工程研究中心浙江杭州310058 浙江省城市地下空间开发工程技术研究中心浙江杭州310058 河海大学岩土工程科学研究所江苏南京210098 浙江省建筑设计研究院浙江杭州310058

基于所收集的16个杭州地铁基坑案例,首先,建立基坑相对“标准化模型”,包括基坑物理参数模型、基坑施工过程模型以及场地土层参数模型,并由此进行三维有限元建模分析;其次,将建模计算的地表沉降值与工程实测、既有文献解进行对比,验证... 详细信息

基于所收集的16个杭州地铁基坑案例,首先,建立基坑相对“标准化模型”,包括基坑物理参数模型、基坑施工过程模型以及场地土层参数模型,并由此进行三维有限元建模分析;其次,将建模计算的地表沉降值与工程实测、既有文献解进行对比,验证所建标准化模型的准确性,并提出考虑全开挖过程的杭州地铁车站基坑坑外任意地表沉降实用计算方法;最后,分析杭州地铁基坑各开挖阶段地表沉降特征。研究结果表明:当开挖深度超过7 m时,坑外地表横向沉降曲线由“悬臂状”转化为“三段式”折线;随挖深的增加,地表沉降显著增大,地表最大沉降的位置距基坑距离也逐渐增大。所建标准化模型和所提实用计算方法具有准确性。

关键词：地铁基坑标准模型全过程开挖横向沉降纵向沉降

Clinical benefit and safety profile of cross-line therapy with CDK4/6 inhibitors: a retrospective study of HR+/HER2–advanced breast cancer

同方期刊数据库博看期刊评论

在线全文

学校读者我要写书评

暂无评论

Cancer Biology & Medicine 2024年第10期 934-950页

作者： Qi Zhao Mingxia Jiang Jiaxuan liu Mengqi Zhang Maiyue He Shihan Zhou Jiani Wang Hongnan Mo Bo Lan Peng Yuan Pin Zhang Fei Ma Qiao li binghe Xu Department of Medical Oncology National Cancer Center/National Clinical Research Center for Cancer/Cancer HospitalChinese Academy of Medical Sciences and Peking Union Medical College

Objective: CDK4/6 inhibitors(CDK4/6is) in combination with endocrine therapy have secured a central role in the treatment of hormone receptor(HR)-positive advanced breast cancer(ABC) and have transformed the therapeutic landscape. Cross-line CDK4/6i therapy in which another CDK4/6i is continued after progression on a prior CDK4/6i may still offer advantageous therapeutic effects. Cross-line CDK4/6i therapy is an area of active investigation in the ongoing pursuit to improve outcomes for patients with HR+/human epidermal growth factor receptor 2(HER2)± ***: This retrospective study enrolled 82 patients with HR+/HER2± ABC who were treated with cross-line CDK4/6is(abemaciclib, palbociclib, ribociclib, and dalpiciclib) after progression with another CDK4/6i. The primary endpoint was progressionfree survival(PFS) according to version 1.1 of the Response Evaluation Criteria in Solid Tumors. Secondary endpoints included toxicity, objective response rate, disease control rate, and overall survival. Adverse events(AEs) were graded according to version 5.0 of the Common Terminology Criteria for Adverse Events, as promulgated by the U.S. Department of Health and Human ***: Eighty-two HR+/HER2± ABC patients who received cross-line CDK4/6i therapy from January 2022 to February 2024 were enrolled. The median age of the patients was 60 years. The median PFS of all patients was 7.6 months(95% CI, 5.9-9.2). Cox regression analysis identified lung metastasis and a switch to endocrine therapy following prior CDK4/6i therapy as independent predictive factors for PFS. Notably, patients who previously received abemaciclib and switched to palbociclib upon disease progression had a median PFS of 10.7 months. The strategy of transitioning to chemotherapy after progression on a prior CDK4/6i, then to a subsequent CDK4/6i merits further investigation. Hematologic toxicity was the most common grade ≥ 3 AEs. No instances of fatal safety events were ***: Cro

关键词：